Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
AssigneeWisconsin Alumni Reseach Foundation
InventorsDavid Frazier Jarrard, Bing Yang
Life of this patent
Estimating the term…
Abstract
A method of detecting the presence of a prostate cancer field defect in a human subject. The method includes (a) obtaining genomic DNA from the human subject and (b) determining methylation status in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2, WNT2, EXT1, and SPAG4, wherein methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
Claims14
A method for detecting methylation in target DNA isolated from prostate tissue, a urine sample, or a semen sample from a subject, the method comprising:
- providing a reaction mixture comprising:
- (1) the target DNA or (2) a bisulfite modified target DNA generated by bisulfite modifying the target DNA, wherein the target DNA comprises SEQ ID NO:101 or a SEQ ID NO:101 allele;
- and
- reacting the reaction mixture to carry out an assay that detects and quantifies methylation at one or more CpG sites within SEQ ID NO:
- 101 or the SEQ ID NO:
- 101 allele of the target DNA.
Dependencies are inferred from the claim text.